Kamada Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Israel · 201-500 Employees
View Company Info for Free
Overview
Headquarters
2 Holzman Street Science Park, Rehovot, ...Phone Number
+972 89406472Website
www.kamada.comRevenue
$174.8 MillionStock Symbol
KMDAIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Kamada Pharmaceuticals
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a late-stage product pipeline. Kamada was founded in 1990 and is headquartered in Rehovot, Israel.Explore more
Kamada Pharmaceuticals Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Kamada Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Kamada Pharmaceuticals had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Kamada Pharmaceuticals is spiking on competitors!
Check if Kamada Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Kamada Pharmaceuticals recently announced quarterly report
Kamada Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Kamada Pharmaceuticals
Funding: Get notified immidiatlly once Kamada Pharmaceuticals has new funding data
Product Launch: Get notified when Kamada Pharmaceuticals launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Kamada Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Kamada Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Kamada Pharmaceuticals.
Kamada Pharmaceuticals financials insights
Gather financial insights about Kamada Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Share Placement
$25M
2022
Other Financing Round
$11.4M
Kamada Pharmaceuticals Tech Stack
A closer look at the technologies used by Kamada Pharmaceuticals
See more technologies
Most Recent Scoops
Hiring Plans
Kamada Pharmaceuticals has more open roles in Medical & Health than it has had at any time in the past 9 months.
Hiring Plans
Earnings
reported gross profit and gross margins for fiscal year 2025 of $76.4 million and 42% respectively, compared to $70 million and 43% respectively in fiscal year 2024. The increase in gross profit is in line with the increase in total revenues, whereas the decrease in gross margin is due to product and market sales mix.
Earnings, Finance
Earnings
reported net income of $20.2 million or $0.35 per diluted share for fiscal year 2025, a 40% increase as compared to net income of $14.5 million or $0.25 per diluted share in fiscal year 2024.
Earnings, Accounting, Financial Reporting, Finance
Earnings
reported operating expenses, including R&D, sales and marketing, G&A, and other expenses totaled $50.2 million in fiscal year 2025 as compared to $49.9 million in fiscal year 2024.
Earnings, Finance
Earnings
Earnings, Finance
Kamada Pharmaceuticals News & Media
Kamada Ltd. Q1 2026 Earnings Call Summary
Moby summary of Kamada Ltd.'s Q1 2026 earnings callKamada Q1 Earnings Call Highlights
Kamada (NASDAQ:KMDA) reiterated its full-year 2026 outlook after reporting first-quarter results that management said were in line with expectations, excluding a temporary shipment delay that shifted revenue into April. Chief Executive Officer Amir London said demand across the company’s product poKamada Q1 2026 Earnings Call: Complete Transcript
On Wednesday, Kamada (NASDAQ:KMDA) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. View the webcast at https://viavid.webcasts.com/starthere.jsp?ei=1760803&tp_key=7219e3b56c Summary Kamada reported first-quarter revenues and adjusted EBITDA in line with expectations, despite a temporary shipment delay, and reiKamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year
REHOVOT, Israel, and HOBOKEN, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced financial results for the three months ended March 31, 2026.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Kamada Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a late-stage product pipeline. Kamada was founded in 1990 and is headquartered in Rehovot, Israel.... Read More
